Life Science Networks
227 episodes listed below
PRESS PLAY
Welcome to the PharmaSource podcast: the pharma and biotech podcast that explores the latest trends, challenges, and commercial opportunities shaping the biopharma manufacturing and outsourcing. In each episode we'll be speaking with top executives, researchers, and outsourcing experts, who share their perspectives on topics such as building a smarter, more sustainable supply chain, how to partner with CDMOs, digital transformation, procurement and external manufacturing strategies, and plenty more besides. Make sure to subscribe for your regular dose of pharma insight.
Based on 6 episodes we listened to · September 2026
Detailed operator interviews reveal the commercial pressures and partnership choices shaping outsourced medicine manufacturing.
PharmaSource Podcast follows the business decisions behind getting medicines manufactured, scaled and delivered. Its interview format puts the host in conversation with biotech leaders and operations specialists, with questions that connect technical constraints to pricing,…
A cancer drug decays within hours; suddenly your supply chain questions come with a stopwatch.
Press play if you want
Short reviews from the PlayNext desk, based on the episodes we processed.
Practical guidance on manufacturing risk, with enough nuance to avoid easy slogans.
This episode offers a practical look at how biotechs de-risk external manufacturing when capacity is tight, and it makes clear there is no single answer that fits every case.
A practical CDMO conversation about partnership, visibility, and the mechanics of outsourced manufacturing.
The episode is a steady look at what makes a CDMO partnership hold together in practice: regulatory discipline, flexible manufacturing, pricing structure, and the kind of operational visibility sponsors need when timelines get tight.
A practical case for partnerships over transactional sourcing.
The episode makes a clear case that pharma supply chains are moving beyond transactional vendor thinking and into longer-term partnerships, shaped by geopolitical uncertainty, sustainability requirements, patient expectations, and the realities of global sourcing.
A practical, industry-focused look at generics, resilience, and the work of building durable pharma capacity.
Markus Zeiger's conversation presents Polpharma as one of Central and Eastern Europe's largest pharmaceutical manufacturers, while tracing his path from Switzerland to the US and then into investment banking and pharma.
Biologics testing is presented as part of moving programs forward, not just a support function.
Charles River's biologics testing work is treated as a necessary part of development and regulatory approval, with Louis Barada linking testing strategy to timelines, sponsor partnerships, and a shifting regulatory landscape.
A blunt look at the business strain now pressing on cell therapy.
This episode stays close to the business reality around cell therapy: funding pressure, manufacturing headaches, and the CDMO pricing model facing emerging biotechs.
A practical radiopharma episode where infrastructure is part of the product.
The episode treats radiopharmaceuticals as a hard operational test, where every weak point shows up fast. Luke and Kostya Pasalidis center the practical problem: therapies that lose time by the hour, specialist facilities, isotope supply, manufacturing, and logistics all have to…
Manufacturing signals, translated into business consequences.
Machine shops, ownership, and industrial purpose.
Raphael Ognar, CEO and co-founder of Enkilt Therapeutics, joins the show to talk through the real pressures facing cell therapy startups.
Brian Gregg, CEO of AmbioPharm, argues that hybrid synthesis, which joins three to five solid-phase-built fragments in liquid phase, improves yield and purification for long peptides such as 39-amino-acid GLP-1s.
Franco Negron, CEO of Simtra BioPharma Solutions, says COVID raised concern about local manufacturing, and that sites in the US and Germany give customers regional options and tariff relief.
Gerry Kennedy, a Keystone Law partner with 20 years of in-house experience at Lonza, says CDMO contracts stall because drafts "go ping pong all over the place," with each markup built on an earlier misunderstanding.
An interview with Louis Barada of Charles River Laboratories, exploring how strategic biologics testing accelerates drug development.
Markus Sieger, CEO of Polpharma Group, reflects on his 25-year journey building the company into a European generic manufacturing leader, discussing topics like supply chain security during COVID, digital transformation, and the importance of company culture.
Cordon Pharma CEO Dr.
Paul Broomhead talks about what makes a CDMO partnership work at the site level.
The episode follows Heijs Vissers, Head of Supply Chain and Procurement and a member of the Executive Committee at Nordic Pharma, as he explains why pharmaceutical supply chains are shifting away from cost-driven transactional thinking.
Reza Oliya starts with Gilead.
Luke opens with the practical problem of delivering a drug that breaks down within hours.
Gil Roth, president of the PBOA, says FDA cuts in February and April 2025 "degraded the FDA," citing extended PDUFA dates and stricter complete response letters.
Campbell Bunce, Chief Scientific Officer at Abzina, says US onshoring and growth in ADCs and AOCs make keeping up with demand the company's main challenge.
Siegfried Chief Scientific Officer Stefan Randall says integrating drug substance and drug product under one CDMO saves time by removing campaign buffers, penalty risk and duplicate quality agreements.
Anand Akambaram, a 30-year vaccine manufacturing veteran of Merck, Bristol-Myers Squibb and CEPI, tells PharmaSource host Dora that FDA vaccine policy shifts have a "chilling effect on innovation," citing two or three startups that lost funding despite promising clinical data.
Amy Gamber, a biotech executive with 20+ years in CMC, says a failing tech transfer is "a business risk," not just a technical problem, because it can run months behind and a million dollars or more over budget.
Daniel Rossetto, head of supply chain and external manufacturing at ArtBio, tells PharmaSource host Luke that radiopharmaceutical doses are made to order with a shelf life of only hours or days, so safety stock of the isotope is 'almost impossible'.
Christopher Frenderson of Dagens Pharma argues that Trump's most-favoured-nation policy creates three main risks for Europe: delayed launches, cancelled launches and higher medicine prices.
Charlie Leon, VP of Manufacturing, Procurement and Logistics at the API Innovation Center (APIC) in St.
Novartis leaders discuss contract manufacturing strategy, partnership models, and operational excellence in biopharma.
This episode explores a new low-waste sterile injectable facility and end-to-end outsourcing solutions for biotech companies.
This episode discusses the integration of AI and digital twins in pharmaceutical manufacturing, addressing regulatory challenges and risk mitigation strategies.
Host Luke Bilton discusses his trip to Boston, the upcoming CDMO Live Americas event, and the External Manufacturing Leaders think tank for biopharma professionals.
A review of 2025's record pharma manufacturing investment in the US and its impact on the contract manufacturing sector, based on CDMO news tracking.
An interview with Julia Schaft about the German biotech ecosystem and the revival of biotech in Germany.
Interview with Kirsten Papenfus about her journey from PhD in tumor immunology to venture building in pharma startups.
A CDMO strategy teardown interview with Explorer's Chief Commercial Officer discussing customer perspective and company vision.
This episode discusses resilience in the biopharma workforce with expert Beth Bernardi-Kennedy, covering definitions, engagement statistics, and strategies to overcome challenges.
Interview with Julien Lézé about transitioning from big pharma to a smaller biotech and managing external manufacturing.